44.36 USD
-0.34 (-0.76%)
SUPN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of SUPN get a neutral evaluation. Nothing too spectacular is happening here. SUPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
In the past 5 years SUPN has always been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.35%, SUPN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.82%, SUPN is in the better half of the industry, outperforming 77.60% of the companies in the same industry.
With a decent Return On Invested Capital value of 2.34%, SUPN is doing good in the industry, outperforming 79.69% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
In the last couple of years the Profit Margin of SUPN has declined.
SUPN's Operating Margin of 6.08% is fine compared to the rest of the industry. SUPN outperforms 79.17% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 89.91%, SUPN belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
SUPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SUPN has more shares outstanding
SUPN has more shares outstanding than it did 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.47 indicates that SUPN is not in any danger for bankruptcy at the moment.
The Altman-Z score of SUPN (5.47) is better than 76.56% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.47 |
ROIC/WACC0.26
WACC8.99%
2.3 Liquidity
SUPN has a Current Ratio of 1.80. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SUPN (1.80) is worse than 65.10% of its industry peers.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN's Quick ratio of 1.56 is on the low side compared to the rest of the industry. SUPN is outperformed by 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
SUPN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.32%.
Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.93% on average per year.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 4.54%.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
The Revenue is expected to grow by 14.90% on average over the next years. This is quite good.
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SUPN is valuated correctly with a Price/Earnings ratio of 14.31.
SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 86.46% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.11. SUPN is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 14.32, SUPN is valued correctly.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 82.29% of the companies in the same industry.
SUPN is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.32 |
4.2 Price Multiples
79.69% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
SUPN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.95 | ||
| EV/EBITDA | 16.97 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.06
EPS Next 2Y2.48%
EPS Next 3Y10.42%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SUPN (12/2/2025, 11:10:54 AM)
44.36
-0.34 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.54%
Inst Owner Change-3.26%
Ins Owners4.2%
Ins Owner Change2.79%
Market Cap2.54B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target61.71 (39.11%)
Short Float %9.48%
Short Ratio5.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)38.13%
PT rev (3m)40.7%
EPS NQ rev (1m)-65.08%
EPS NQ rev (3m)-55.75%
EPS NY rev (1m)17.89%
EPS NY rev (3m)24.84%
Revenue NQ rev (1m)-3.13%
Revenue NQ rev (3m)1.01%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)3.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.32 | ||
| P/S | 3.73 | ||
| P/FCF | 35.95 | ||
| P/OCF | 35.39 | ||
| P/B | 2.42 | ||
| P/tB | 8.28 | ||
| EV/EBITDA | 16.97 |
EPS(TTM)3.1
EY6.99%
EPS(NY)3.1
Fwd EY6.98%
FCF(TTM)1.23
FCFY2.78%
OCF(TTM)1.25
OCFY2.83%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.06
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 5.47 |
F-Score4
WACC8.99%
ROIC/WACC0.26
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.31 and the Price/Book (PB) ratio is 2.42.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.